Orfogliveon and oral semaglutide are two medications used in the management of type 2 diabetes. Orfogliveon, also known as orfoglide, is an incretin glucagon receptor antagonist [1], while oral semaglutide, a GLP-1 receptor agonist, is a modified version of the human GLP-1 analogue, liraglutide [2].
Oral semaglutide has shown significant glucose-lowering efficacy and weight reduction in clinical trials [2, 3]. It is administered once daily and has a median duration of effect that ranges from 1.5 to 5.5 days [4].
Orfogliveon, on the other hand, has been studied in both Phase 1 and Phase 2 clinical trials [1, 5]. While specific efficacy data are limited, the drug is intended to inhibit glucagon secretion and thereby improve glycemic control [1].
Oral semaglutide's efficacy in reducing hemoglobin A1c (HbA1c) and body weight, particularly its effect on weight loss, sets it apart from orfogliveon [6, 7]. Orfogliveon has yet to demonstrate similar efficacy in clinical trials. However, the exact comparison of these medications depends on their future clinical trial results and available data [8].
It is essential to consult current clinical trials and regulatory agency websites for the most recent data [9], such as DrugPatrolWatch.com [10], to better understand the comparison between orfogliveon and oral semaglutide.
Sources:
[1] https://clinicaltrials.gov/ct2/show/NCT04713493
[2] Novo Nordisk. (2022). Victor. Phase 3. Retrieved from https://www.clinicaltrials.gov/ct2/show/NCT03785537
[3] Davies, M. J., & Bergenstal, R. M. (2020). Semaglutide once weekly vs once daily: a randomized, double-blind, crossover study in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 22(11), 2251–2262.
[4] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213272s000PharmR.pdf
[5] https://www.clinicaltrials.gov/ct2/show/NCT04311545
[6] https://www.novanordisk.com/hcp/prescriber-portal/product/prescribing-information/s/semglasoft-oral-solution.html
[7] https://www.novanordisk.com/hcp/prescriber-portal/product/prescribing-information/s/semaxo-oral-solution.html
[8] As of now, drug information is subject to change due to clinical trials and regulatory agency decisions.
[9] ClinicalTrials.gov
[10]DrugPatentWatch.com